Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
Curr Opin Rheumatol. 2021 Mar 1;33(2):181-189. doi: 10.1097/BOR.0000000000000772.
This review gives an overview of the recently published clinical trials in systemic lupus erythematosus (SLE).
Our continuously improving understanding of the cellular and molecular mechanisms, which are involved in the pathogenesis of SLE, has inspired the performance of multiple clinical trials in an attempt to modify recognized targets. Here, we summarize results obtained from recent trials, which used monoclonal antibodies blocking cytokines, blockers of costimulatory molecules or deleting immune cells, small drug inhibitors of kinases and replenishment of cytokines.
The therapeutic options for patients with SLE grow continuously and in parallel it raises the need for pathogenetic mechanism-based precision medicine so that we may select the right treatment for the right patient.
本文对最近发表的系统性红斑狼疮（SLE）临床试验进行综述。
我们对参与 SLE 发病机制的细胞和分子机制的认识不断提高，激发了多项临床试验，试图改变已确定的靶点。在这里，我们总结了最近使用阻断细胞因子的单克隆抗体、共刺激分子阻断剂或清除免疫细胞、激酶的小分子药物抑制剂和细胞因子补充的临床试验的结果。
SLE 患者的治疗选择不断增加，同时也需要基于发病机制的精准医学，以便为合适的患者选择合适的治疗方法。
